Emmaus Life Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Sep. 30, 2012	$ (13,074,700)us-gaap_StockholdersEquity	$ 1,900	$ 32,566,700	$ (45,643,300)
Balance (in shares) at Sep. 30, 2012		1,914,175
Stock-based compensation	1,257,300	0	1,257,300	0
Valuation of warrants issued for debt	30,400	0	30,400	0
Stock issued for officer's salaries	7,900	200	7,700	0
Stock issued for officer's salaries (in shares)		165,790
October 2010 Notes: Senior subordinated convertible notes	3,789,200	14,200	3,775,000	0
October 2010 Notes: Senior subordinated convertible notes (in shares)		14,246,852
January 2011 Notes: Subordinated convertible notes	3,000,600	8,500	2,992,100	0
January 2011 Notes: Subordinated convertible notes (in shares)		8,503,003
October 2011 Notes: Subordinated convertible notes	2,301,400	9,200	2,292,200	0
October 2011 Notes: Subordinated convertible notes (in shares)		9,205,680
February 2012 Notes: Unsecured convertible note	101,900	400	101,500	0
February 2012 Notes: Unsecured convertible note (in shares)		407,700
October 2012 Notes: Unsecured convertible notes	2,080,000	44,100	2,035,900	0
October 2012 Notes: Unsecured convertible notes (in shares)		44,085,044
Stock issued for private placement of shares	2,958,800	12,200	2,946,600	0
Stock issued for private placement of shares (in shares)		12,180,000
Stock issued in lieu of cash to creditors	502,100	2,000	500,100	0
Stock issued in lieu of cash to creditors (in shares)		2,008,318
Inducement to convert debt	5,792,500	0	5,792,500	0
Net loss	(10,907,400)us-gaap_NetIncomeLoss	0	0	(10,907,400)
Balance at Sep. 30, 2013	(2,160,000)us-gaap_StockholdersEquity	92,700	54,298,000	(56,550,700)
Balance (in shares) at Sep. 30, 2013		92,716,562
Stock-based compensation	1,008,700	0	1,008,700	0
Stock issued for private placement of shares	1,691,000	7,000	1,684,000	0
Stock issued for private placement of shares (in shares)		6,940,000
Stock issued in lieu of cash to creditors	361,500	1,400	360,100	0
Stock issued in lieu of cash to creditors (in shares)		1,446,380
Stock issued for cashless exercise of warrants	0	600	(600)	0
Stock issued for cashless exercise of warrants (in shares)		564,467
Net loss	(2,662,800)us-gaap_NetIncomeLoss	0	0	(2,662,800)
Balance at Sep. 30, 2014	$ (1,761,600)us-gaap_StockholdersEquity	$ 101,700	$ 57,350,200	$ (59,213,500)
Balance (in shares) at Sep. 30, 2014		101,667,409